|
|
|
Serum Occludin as a Biomarker to Predict the Severity of Acute Ischemic Stroke, Hemorrhagic Transformation, and Patient Prognosis
|
|
Li Weili, Qi Zhifeng, Kang Huining, Qin Xuzhen, Song Haiqing, Sui Xueqin, Ren Yi, Ji Xunming, Ma Qingfeng, Jian Liu Ke
|
|
| |
| Table 3 Baseline characteristics of HT and non-HT groups in CI patients. |
|
| Variable | HT
(n=19) | Non-HT
(n=147) | P values |
|---|
| Age — yr | 68.68±12.49 | 66.15±12.77 | 0.416 | | Male sex — no. (%) | 16 (84.2) | 107 (72.8) | 0.285 | | Atrial fibrillation — no. (%) | 6 (31.6) | 32 (21.8) | 0.338 | | Diabetes mellitus — no. (%) | 6 (31.6) | 40 (27.2) | 0.689 | | Hypertension — no. (%) | 7 (36.8) | 60 (40.8) | 0.740 | | Median NIHSS score (IQR) | 12 (6-15) | 5 (2-11) | <0.001 | | Previous stroke — no. (%) | 5 (26.3) | 30 (20.4) | 0.552 | | Median Onset to Door time— hr. (IQR) | 5 (2.5-8) | 4.1 (2.3-7) | 0.352 | | IVT therapy | 7 (36.8) | 45 (30.6) | 0.582 | | GLU (mmol/L) | 9.05±3.25 | 8.48±4.09 | 0.673 | | FIB (g/L) | 3.0±0.89 | 3.43±1.07 | 0.232 |
|
|
|